Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
Pharmaceutical Innovation in Europe
New pharmaceutical breakthroughs approaching – is the system set up to fund them all?
The advent of new potential blockbusters in Europe is anticipated to position the pharmaceutical industry on a sustained growth pattern through 2022 (2015-2022 CAGR at 3.2%). While oncology is set to take the lion’s share in terms of growth, innovations have been emerging across several therapy areas.
Among the top 10 bestselling products in 2022 the crown is expected to move from Humira to Xarelto while five therapies will be addressing unmet needs in cancer. As the pharmaceutical pipeline continues to meet the demand for improved outcomes, question marks on the sustainability of the system as we know it continue to rise.
The analysis in this report is based on Evaluate European Drug Forecasts - the first standardised consensus based drug forecasts for Europe.
European Drug Forecasts offers a new unique solution for European market sizing, R&D horizon scanning and price comparison sourced to government and company reported sales data with European country level, consensus based forecasts to 2022. Find out more.
Confirm your details on form below to download this report